Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between
Hyo S. Han, Praveen Vikas, Ricardo Costa, Nusrat Jahan, Ammanuel Taye, Erica Stringer-Reasor
Abstract
Triple-negative breast cancer (TNBC) is a very heterogeneous and aggressive breast cancer subtype with a high risk of mortality, even if diagnosed early. The mainstay of early-stage breast cancer includes systemic chemotherapy and surgery, with or without radiation therapy. More recently, immunotherapy is approved to treat TNBC, but managing immune-rated adverse events while balancing efficacy is a challenge. The purpose of this review is to highlight the current treatment recommendations for early-stage TNBC and the management of immunotherapy toxicities.
Topics & Concepts
Triple-negative breast cancerMedicineBreast cancerImmunotherapyOncologyStage (stratigraphy)Internal medicineRadiation therapyChemotherapyAdverse effectCancerPaleontologyBiologyCancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsCancer Cells and Metastasis